Lonza Signs Manufacturing Deal with Femta Pharmaceuticals

Lonza says it has signed a manufacturing services agreement with Femta Pharmaceuticals (San Diego, CA), to facilitate the development and manufacturing of FM101, a high affinity monoclonal antibody in late pre-clinical development for the treatment of rheumatoid arthritis. The agreement gives Femta access to Lonza’s GS Gene Expression System along with cell line, purification and process development to support a cGMP process for Femta’s clinical development program. “By leveraging Lonza’s considerable expertise in gene expression and...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers